NVCN - ネオバスク （Neovasc Inc.）

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the…

VANCOUVER and MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal clinical trial the Company is executing for the Neovasc Reducer™ (“Reducer”) towards an approval decision for the device in the United States. The Trial will randomize approximately 380 patients at up to 50 sites in North America. To date, 55 patients have been enrolled at 17 active sites. The Company has undertaken several initiatives to further accelerate enrollment in the Trial, including machine learning technology, expanding the field clinical team, and initiating enrollments in Canada. Neovasc aims to complete randomization in the first half of 2024.

VANCOUVER and MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal - Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy

Neovasc Inc. - Investment analysts at HC Wainwright upped their FY2022 earnings estimates for shares of Neovasc in a research note issued on Tuesday, November 15th. HC…

Neovasc Inc. (NASDAQ:NASDAQ:NVCN) Q3 2022 Earnings Conference Call November 10, 2022 04:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President & Chief…

Major players in the prosthetic heart valve devices and equipment market are Boston Scientific, Edward life sciences, Medtronic, Livanova, Abbott, Jenavalve technology, Lepu medical, Cryolife, Neovasc Inc, and St. Major players in the prosthetic heart valve devices and equipment market are Boston Scientific, Edward life sciences, Medtronic, Livanova, Abbott, Jenavalve technology, Lepu medical, Cryolife, Neovasc Inc, and St.

Neovasc press release (NVCN): Q4 GAAP EPS of -$0.40 misses by $0.30.Revenue of $2.54M (+29.6% Y/Y) beats by $1.74M.

VANCOUVER and MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021.

VANCOUVER, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on March 10, 2022.

VANCOUVER, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on March 10, 2022.

VANCOUVER and MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022. Additionally, the Company announced the 500th patient has been treated in Germany.

VANCOUVER and MINNEAPOLIS, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022. A recorded presentation by Fred Colen, Neovasc''s Chief Executive Officer, will be available on the conference website starting at 7:00 am EST on Monday, January 10. The recording will be archived for 90 days. About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its … Full story available on Benzinga.com

Neovasc Inc (NVCN) shares closed today at just slightly above its 52 week low of $0.45, giving the company a market cap of $30M. The stock is currently down 52.3% year-to-date, down 58.4% over the past 12 months, and down 100.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 47.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

XL Fleet Corp. (NYSE:XL) with the stream of -14.02% also noticed, India Neovasc Inc. (NASDAQ:NVCN) encountered a rapid change of -5.45% in the last hour of Tuesdays trading session. XL The post Miraculous Stock: XL Fleet Corp. (NYSE:XL), Neovasc Inc. (NASDAQ:NVCN) appeared first on Stocks Equity .